Ludwig Felber, co-founder and former Managing Director of investment bank Viscardi AG, has been appointed as Chief Financial Officer and member of the Executive Board, effective immediately. At Viscardi, Mr. Felber has been Head of Healthcare Investment Banking with responsibility for all corporate finance activities in the life sciences industry. Previously, he has been responsible for the German, Austrian and Swiss healthcare activities of the US investment bank Cowen & Company and for HypoVereinsbank's M&A advisory services for life science companies having worked in Munich and New York. Beforehand Mr. Felber worked for Lehman Brothers in Frankfurt and London as well as for the investment banks of HypoVereinsbank in Tokyo and New York. He has been involved in numerous leading corporate finance transactions in the European Life Sciences Industry.
Mr. Felber studied business administration majoring in law at the University of Oldenburg and received his MBA from the Babcock Graduate School of Management at Wake Forest University, Winston-Salem.
Oliver Borrmann, Chairman of the Supervisory Board of Revotar, stated: "Mr. Felber is an ideal fit as CFO of Revotar. His long standing experience and impressive track record is a perfect match with Revotar's strategy to bring the Company to the next stage."
In addition, Dr Martin Pöhlchen, CEO of Revotar, has been appointed to President & CEO of the Company. Revotar Pharmaceuticals AG furthermore announced the election of Prof Dr Wolfgang Hartwig, Managing Director of Pharma R&D Consulting GmbH, Wuppertal and former Global Head of Pharmaceutical Research and Development of Bayer HealthCare AG's Pharmaceutical Division, as new member for Revotar's Supervisory Board and his appointment as Vice Chairman of the Board. He is replacing Dr Horst Witzel, formerly Chairman of the Board of Executive Directors of Schering AG, in this function.
Prof Dr Wolfgang Hartwig has profound experience in the global pharmaceutical industry. Among others, he served as Executive Vice President, and as Global Head of Bayer HealthCare's (BHC's) Pharmaceutical Research and Development and Chairman of BHC's Research and Development Committee he has been responsible for the global pharma research activities of the company. In addition, he has been Head of the International Pharmaceutical Research at Bayer AG, member of the Management Committee of the Pharmaceuticals Business Group, and President & CEO of the Bayer Diagnostics Division.
Prof Dr Wolfgang Hartwig has served on numerous public management and advisory boards, including the Senatsausschuss of the Helmholtz Association and the National Genome Research Network and is at present member of the board of several biotech and pharmaceutical companies, including Xention Discovery Ltd. (London, UK), Axxam SpA (Milan, Italy) and Sygnis AG (Heidelberg, Germany). He also is Executive Consultant to the Bayer Holding Board. Prof Dr Wolfgang Hartwig holds a doctoral degree in organic chemistry from the University of Göttingen and is Honorary Professor at the Westfälische Wilhelms-University of Münster.
Dr Martin Pöhlchen, President & CEO of Revotar Biopharmaceuticals AG, said: "We are delighted that we were able to attract Professor Hartwig as a new member for Revotar's Supervisory Board. Revotar will greatly benefit from his international industry background and his broad experience in the research and development of pharmaceuticals. On behalf of Revotar I would also like to thank Dr Witzel very much for his outstanding support and successful work for more than ten years."
About Revotar Biopharmaceutical AG
Revotar develops innovative drugs for inflammatory indications such as psoriasis, asthma, chronic obstructive pulmonary disease (COPD) and acute lung injury (ALI). Its lead candidate Bimosiamose, a pan-selectin antagonist, has already passed several clinical phase I and phase IIa trials in asthma, COPD and psoriasis with a good safety and efficacy profile in nearly 200 patients and volunteers. In summer 2006, Revotar announced a Start-Up Development Agreement with a US Pharma company for the further development of Bimosiamose in one major disease area. In September 2008, Revotar announced the successful first closing of its Series A financing round of 5.3 million EUR, with an additional commitment of 3 million EUR based on certain preconditions to be met.
